India boasts a flourishing biosimilar landscape, with over 100 biopharmaceutical businesses manufacturing and marketing these products. Regulatory authorities in India refer to biosimilars as “similar biologics.” Despite India being an early adopter of the concept, there initially existed no clearly defined guidelines for “similar biologics.”
In accordance with the regulations established by the Bar Council of India, we wish to apprise you that our engagement in solicitation or any form of advertising is strictly prohibited. By proceeding beyond this point and selecting the "I Agree" option below, you expressly acknowledge that any transmission, receipt, or utilization of the information provided on our website does not constitute solicitation, advertisement, inducement, or personal communication intended to establish an attorney-client relationship on behalf of the Firm.
It is imperative to understand that the information presented herein is not to be construed as legal advice. Users are strongly advised to conduct independent inquiries to address their specific legal concerns.
While meticulous efforts have been exerted to ensure the accuracy of the content contained within this website, United & United unequivocally disclaims any and all liability arising from reliance placed upon such information by the user or any third party. Your diligence and discretion in interpreting and utilizing the contents of this website are paramount, and we appreciate your understanding of these guidelines.
